[go: up one dir, main page]

BRPI0510617A - uso de expressão de il-17 para prever inflamação de pele; processos de tratamento - Google Patents

uso de expressão de il-17 para prever inflamação de pele; processos de tratamento

Info

Publication number
BRPI0510617A
BRPI0510617A BRPI0510617-6A BRPI0510617A BRPI0510617A BR PI0510617 A BRPI0510617 A BR PI0510617A BR PI0510617 A BRPI0510617 A BR PI0510617A BR PI0510617 A BRPI0510617 A BR PI0510617A
Authority
BR
Brazil
Prior art keywords
expression
skin inflammation
treatment processes
predict skin
predict
Prior art date
Application number
BRPI0510617-6A
Other languages
English (en)
Inventor
Robert A Kastelein
Terrill K Mcclanahan
Erin Murphy
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0510617A publication Critical patent/BRPI0510617A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

USO DE EXPRESSãO DE IL-17 PARA PREVER INFLAMAçãO DE PELE; PROCESSOS DE TRATAMENTO. A presente invenção refere-se a processos para diagnóstico de tendência de um sujeito a desenvolvimento de inflamação de pele, em particular, psoríase. Também são providos processos de tratamento com antagonistas de IL-17 e/ou IL-23.
BRPI0510617-6A 2004-05-03 2005-05-02 uso de expressão de il-17 para prever inflamação de pele; processos de tratamento BRPI0510617A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56774704P 2004-05-03 2004-05-03
PCT/US2005/014720 WO2005108616A1 (en) 2004-05-03 2005-05-02 Use of il-17 expression to predict skin inflammation; methods of treatment

Publications (1)

Publication Number Publication Date
BRPI0510617A true BRPI0510617A (pt) 2007-10-30

Family

ID=34967584

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510617-6A BRPI0510617A (pt) 2004-05-03 2005-05-02 uso de expressão de il-17 para prever inflamação de pele; processos de tratamento

Country Status (11)

Country Link
US (2) US7501247B2 (pt)
EP (1) EP1761643A1 (pt)
JP (1) JP2007535930A (pt)
CN (1) CN1993480A (pt)
AU (1) AU2005241020B2 (pt)
BR (1) BRPI0510617A (pt)
CA (1) CA2565566A1 (pt)
MX (1) MXPA06012754A (pt)
NO (1) NO20065560L (pt)
WO (1) WO2005108616A1 (pt)
ZA (1) ZA200609140B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP2108660A1 (en) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition of IL-17 production
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
EP1761643A1 (en) * 2004-05-03 2007-03-14 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
US7704503B2 (en) * 2005-02-14 2010-04-27 Wyeth Llc Use of IL-17F in diagnosis and therapy of airway inflammation
PL1896073T3 (pl) 2005-06-30 2013-08-30 Janssen Biotech Inc Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
DE602006009834D1 (de) * 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
PT1971366E (pt) * 2005-12-29 2014-11-06 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
WO2007149814A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
AR063683A1 (es) 2006-08-11 2009-02-11 Schering Corp Anticuerpos para il-17a
EP2425838A3 (en) * 2007-02-28 2012-05-02 Schering Corporation Combination therapy for treatment of immune disorders
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009136286A2 (en) 2008-05-05 2009-11-12 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2626437A3 (en) 2008-05-14 2013-12-11 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP2419535B1 (en) * 2009-04-15 2022-08-17 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA029283B1 (ru) 2009-10-30 2018-03-30 Янссен Байотек, Инк. Антагонисты il-17a
KR102049223B1 (ko) 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항－ｉｌ－２３ 항체
KR102066295B1 (ko) 2011-06-27 2020-01-14 갈데르마 리써어치 앤드 디벨로프먼트 신규한 여드름용 ｔｈ１７ 분화 마커 및 이의 용도
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
WO2013165791A1 (en) 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
EP2852615B1 (en) 2012-05-22 2018-12-05 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
SG11201701423RA (en) 2014-09-03 2017-03-30 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
WO2017011260A1 (en) * 2015-07-16 2017-01-19 Eli Lilly And Company Treatment of pruritus
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
JP7186094B2 (ja) 2016-05-06 2022-12-08 イグジキュア オペレーティング カンパニー インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
EP3762015A4 (en) 2018-03-05 2022-04-27 Janssen Biotech, Inc. METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
EP3813678A4 (en) * 2018-05-09 2022-06-08 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
CA2328496C (en) * 1998-05-15 2016-01-05 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
PT1897944E (pt) * 1999-12-23 2011-11-28 Genentech Inc Polipéptidos homólogos de il-17 e suas utilizações terapêuticas
PT1287130E (pt) * 2000-05-10 2008-09-01 Schering Corp Proteínas de subunidades de receptores de citocinas de mamífero, métodos e reagentes relacionados
ES2360481T3 (es) * 2001-01-25 2011-06-06 Zymogenetics, Inc. Procedimiento para tratar psoriasis usando un antagonista de il- 17d.
US20020169127A1 (en) * 2001-03-29 2002-11-14 Charmley Patrick R. Compositions and methods for diagnosing or treating psoriasis
EP2108660A1 (en) * 2002-10-30 2009-10-14 Genentech, Inc. Inhibition of IL-17 production
JP4902961B2 (ja) * 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途；関連試薬
EP1589998B1 (en) 2002-12-31 2011-04-27 Schering Corporation IL-27 and IL-2 for use in the treatment of cancer
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
EP3594228A1 (en) * 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7183057B2 (en) * 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
EP1761643A1 (en) * 2004-05-03 2007-03-14 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment

Also Published As

Publication number Publication date
US20090028860A1 (en) 2009-01-29
CA2565566A1 (en) 2005-11-17
AU2005241020A1 (en) 2005-11-17
JP2007535930A (ja) 2007-12-13
WO2005108616A1 (en) 2005-11-17
NO20065560L (no) 2006-12-01
CN1993480A (zh) 2007-07-04
MXPA06012754A (es) 2007-02-19
AU2005241020B2 (en) 2008-07-10
US7776540B2 (en) 2010-08-17
US20050244874A1 (en) 2005-11-03
EP1761643A1 (en) 2007-03-14
ZA200609140B (en) 2007-11-28
US7501247B2 (en) 2009-03-10

Similar Documents

Publication Publication Date Title
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BRPI0916138A2 (pt) "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2007001665A1 (es) Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX2008016453A (es) Composiciones y metodos para tratar infecciones parasitas.
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
WO2010068794A3 (en) Hif inhibitors and use thereof
MY158428A (en) Topical composition for the treatment of actinic keratosis
WO2007143211A3 (en) Methods for identifying agents and their use for the prevention of restenosis
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]